Palindrome Pharma Launches in Canada to Broaden Access to Biosimilars

Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, has launched in Canada, aiming to broaden access to high-quality biologic therapies and contribute to a more sustainable healthcare system. The company’s official launch was announced on October 7, 2026, in Toronto, Ontario.

Founded by Dr. Jeremy B. Desai, the company is committed to identifying and commercializing biosimilar medicines that will address the growing demand for biologic treatments in Canada. Palindrome Pharma plans to build a diversified portfolio across selected therapeutic areas, supported by capabilities in regulatory affairs, market access, medical affairs, commercialization, and patient support programs.

The company’s approach is guided by four key priorities: 1. Patient Access: Palindrome Pharma will use real-world evidence with a focused market strategy to help more Canadians benefit from important biologic treatment options. 2. Quality and Reliability: The company will work with experienced partners and maintain rigorous standards across the product lifecycle. 3. Healthcare Sustainability: Palindrome Pharma aims to help healthcare systems realize the value offered by biosimilars. 4. Partnership: The company will build transparent, enduring relationships with patients, healthcare professionals, governments, payers, and industry partners.

The launch of Palindrome Pharma marks a significant step in the Canadian biosimilars market, as the company seeks to address the growing demand for biologic medicines and improve patient access to these therapies. The company’s mission is to close the gap, one biosimilar at a time, through strategic partnerships and dedicated Canadian capabilities.

The company’s commitment to quality and reliability is underscored by its rigorous standards and focus on maintaining high levels of safety and efficacy in its biosimilar medicines. Palindrome Pharma is committed to building a portfolio of biosimilar medicines that will address the needs of patients and healthcare professionals across various therapeutic areas.

In conclusion, the launch of Palindrome Pharma in Canada is a significant development in the biosimilars market, as the company aims to play a pivotal role in improving patient access to high-quality biologic therapies and contributing to the sustainability of the Canadian healthcare system.